



May 18, 2020

VIA Electronic Mail

Stewart I. Edington
President/CEO
Dougherty's Pharmacy
5924 Royal Lane Suite 250
Dallas, Texas 75230-3890

Mr. Edington:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Dougherty's Pharmacy, located at 5959 Royal Lane Suite 515 Dallas, TX 75230-3890, from June 19, 2019, to July 1, 2019, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Texas State Board of Pharmacy for follow up.

When the Agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Dr. Shawn Larson - Compliance Officer, at phone number 214-253-5216, or by email at Shawn.Larson@FDA.HHS.GOV.

Sincerely,

**John W.
Diehl -S3**

Digitally signed by John W. Diehl -S3
DN: c=US, o=U.S. Government,
ou=HHS, ou=FDA, ou=People,
cn=John W. Diehl -S3,
0.9.2342.19200300.100.1.1=20000997
27
Date: 2020.05.18 11:40:33 -05'00'

CDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Enclosure: EIR, SRL

Cc: Allison Vordenbaumen Benz
Executive Director
Texas State Board of Pharmacy (cover letter only)
333 Guadalupe, Suite #3-500
Austin, TX 78701

U.S. Food & Drug Administration
Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204
www.fda.gov